Trakya University
Edirne, Turkey (Türkiye)
NCT Number: NCT07469137
Patients diagnosed with heart failure at our clinic who routinely undergo CRT implantation will be included in the study. This decision is independent of the study. In patients included in the study, after routine placement of a coronary sinus catheter, 2 cc of blood will be drawn from this catheter without performing any additional invasive procedures on the patient. Additionally, one peripheral blood sample will be collected from the patient's routinely accessed antebrachial vein. The blood samples will be centrifuged at 4000 rpm (revolutions per minute) for 10 minutes to separate the serum and stored at -80 °C until analyzed. The demographic, clinical, laboratory, electrocardiographic, and echocardiographic data of these patients will be recorded. At the 6-month follow-up clinic visit after discharge, routine heart failure parameters, routine echocardiographic data, and routine ECG recordings will be obtained. The procedures to be performed after discharge are routine for patients who have undergone CRT implantation at our clinic, and no additional follow-up or tests will be performed for this study. After all data are recorded, statistical evaluation will be performed. Data will be reviewed through the ENLİL HBYS system. The best criteria for determining CRT response have not been clearly established. Many studies have been conducted to predict CRT response in advance. A review of the literature shows that YKL-40 levels in the blood are associated with cardiovascular diseases, but no study in the literature has shown the relationship between YKL-40 levels and CRT implantation in patients.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Observational
Edirne, Turkey (Türkiye)
Patients diagnosed with heart failure who are under follow-up and have an EF <35 despite optimal medical treatment, and whose functional capacity is 2-3, or patients diagnosed with heart failure who routinely undergo CRT implantation at our clinic due to high-degree block will be included in the study. This decision was made independently of the study. Patients routinely undergo permanent pacemaker implantation with leads placed in the right ventricle, coronary sinus, and right atrium. In patients included in the study, after routine placement of the coronary sinus catheter, 2 cc of blood will be drawn from this catheter without performing any additional invasive procedures on the patient. In addition, one peripheral blood sample will be drawn from the patient's routinely opened antebrachial vein. The blood samples will be centrifuged at 4000 rpm (revolutions per minute) for 10 minutes to separate the serum and stored at -80 °C until analyzed. The demographic, clinical, laboratory, electrocardiographic, and echocardiographic data of these patients will be recorded. At the 6-month follow-up clinic visit after discharge, routine heart failure parameters, routine echocardiographic data, and routine ECG recordings will be obtained. The procedures to be performed after discharge are routine for patients who have undergone CRT implantation at our clinic, and no additional follow-up or tests will be performed for this study. After all data are recorded, statistical evaluation will be performed. Data will be reviewed via the ENLİL HBYS system. In the literature, patients with KRT are grouped as RESPONDERS and NON-RESPONDERS. Although the best criteria for determining KRT response have not been clearly established, three categories can be considered in the evaluation. The first is clinical measurements (New York Heart Association classification, functional capacity, etc.), the second is the assessment of left ventricular reverse remodeling (increase in ejection fraction on echocardiography, decrease in left ventricular end-systolic and end-diastolic volume), and the third is the reduction in heart failure-related hospitalization and all-cause mortality during follow-up. In addition, individual factors may also influence the outcome. These factors include genetic and gender differences, left ventricular lead position, left ventricular scarring in ischemic patients, and atrial fibrillation. Patients who are NON RESPONDERS are less likely to benefit from CRT, which is an undesirable outcome for invasive treatment. Patients with pacemakers are at risk for foreign body infection and infective endocarditis, and the presence of a device that does not enhance cardiac function is undesirable. Many studies have been conducted to predict the response to CRT. Reviewing the literature, it has been shown that YKL-40 levels in the blood are associated with cardiovascular diseases; however, no study in the literature has shown the relationship between YKL-40 levels and cardiac resynchronization therapy implantation in patients.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline and 6 months
Serum YKL-40 levels measured during cardiac resynchronization therapy (CRT) will be evaluated in conjunction with the CRT response during the patient's routine 6-month follow-up after the procedure. Patients are those for whom the decision to undergo the procedure was made independently of the study. Follow-ups are routine; there is no additional follow-up for the study.
Trakya University
Other
RELATIONSHIP BETWEEN YKL-40 LEVELS IN CORONARY SINUS AND PERIPHERAL BLOOD DURING CARDIAC RESYNCHRONIZATION THERAPY (CRT) PROCEDURE AND CRT RESPONSE IN FOLLOW-UPS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07538596
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Istanbul, Kadikoy, Turkey (Türkiye)
View Trial DetailsNCT02690974
Cardiovascular Diseases, Heart Diseases
Edmonton, Alberta, Canada
View Trial DetailsNCT05572957
Arrhythmias, Cardiac, Bundle-Branch Block
Beijing, Beijing Municipality, China
View Trial DetailsNCT05652218
Arrhythmias, Cardiac, Bundle-Branch Block
Durham, North Carolina, United States
View Trial Details